Perelman School of Medicine at the University of Pennsylvania

Wherry Lab

  • banner image
  • wherry lab logo

E. John Wherry, PhD

E John Wherry, PhD  Richard and Barbara Schiffrin President's
  Distinguished Professor of Microbiology  
  Director, Institute for Immunology
  University of Pennsylvania 
  354 BRB II/III 
  421 Curie Boulevard 
  Philadelphia, PA 19104-6160
  Email Address

Lab in the News

Congratulations to Jonathan Johnnidis for successfully defending his thesis!! 

                      


Immune Atlases Created for Kidney, Lung Cancers

E. John Wherry, PhD, director of the Institute for Immunology, is quoted on a study exploring the creation of comprehensive “immune atlases” of cancers. He notes that the challenge is to translate this information into targeted therapies.


Industry "Road Tests" New Wave of Immune Checkpoints

John Wherry, PhD, a professor of Microbiology, comments on the success of immune checkpoint inhibitors in oncology, “Through intelligence or just luck, we managed to stumble on the two most fundamental of these inhibitory receptors early on. There are clearly secondary pathways that play a fundamental role. And then there may be tertiary pathways that are context-specific or cell-type-specific.”


Stability of Exhausted T Cells Limits Cancer Checkpoint Drugs

E. John Wherry, PhD, director of the Institute for Immunology and a professor of Microbiology, published in Science. Reinvigorating exhausted T cells in mice using a PD-L1 blockade caused few T memory cells to develop.
News ReleaseCancer Research UK • AJMC.com


Penn Team Tracks Rare T Cells in Blood to Better Understand Annual Flu Vaccine

A team led by researchers from the Perelman School of Medicine at the University of Pennsylvania has found a way to identify the small population of cTfh present in the blood after an annual flu vaccine to monitor their contribution to antibody strength. They published their findings in Science Immunology this week. The studies, led by Ramin Herati, MD, an instructor of Infectious Disease, used high dimensional immune-cell profiling and specific genomic tests to identify and track these rare cells over time.